CAJ | 학술논문

目的：：观察普瑞巴林( PGB )和卡马西平( CBZ )对原发性三叉神经痛( PTN )患者血浆 P 物质( SP )和降钙素基因相关肽( CGRP)以及疼痛视觉模拟评分( VAS)的影响，评估PGB治疗PTN的疗效和安全性。方法：130例PTN患者随机分为观察组64例使用PGB治疗，对照组66例使用CBZ治疗。分别从低剂量开始给药，观察患者的疗效及不良反应至第4周末，两组患者在治疗前和结束时以放免法测定血浆SP和CGRP含量，并进行VAS评分。结果：观察组患者的总有效率89.1%，对照组72.1%，两组患者差异有统计学意义(P<0.05)；治疗后两组患者的血浆SP和CGRP均下降，观察组患者较对照组尤为明显(P<0.05)。观察组不良反应发生率31.3%明显低于对照组59.1%。结论：PGB治疗PTN疗效和安全性均高于CBZ。
목적：：관찰보서파림( PGB )화잡마서평( CBZ )대원발성삼차신경통( PTN )환자혈장 P 물질( SP )화강개소기인상관태( CGRP)이급동통시각모의평분( VAS)적영향，평고PGB치료PTN적료효화안전성。방법：130례PTN환자수궤분위관찰조64례사용PGB치료，대조조66례사용CBZ치료。분별종저제량개시급약，관찰환자적료효급불량반응지제4주말，량조환자재치료전화결속시이방면법측정혈장SP화CGRP함량，병진행VAS평분。결과：관찰조환자적총유효솔89.1%，대조조72.1%，량조환자차이유통계학의의(P<0.05)；치료후량조환자적혈장SP화CGRP균하강，관찰조환자교대조조우위명현(P<0.05)。관찰조불량반응발생솔31.3%명현저우대조조59.1%。결론：PGB치료PTN료효화안전성균고우CBZ。
Objective:To observe influence of Pregabalin ( PGB) and Carbamazepine ( CBZ) on plasma substance P ( SP) , calcitonin gene-related peptide ( CGRP) , and pain visual analogue score ( VAS) for patients with trigeminal neuralgia ( PTN) , and e﹣valuate efficacy and safety of PGB in treatment of PTN. Methods:130 patients with PTN were randomly divided into observation group ( PGB, 64 cases) and control group ( CBZ, 66 cases) . Both groups were administered with low dose at first, and then the therapeutic effect and adverse effect until termination of the fourth week were observed. The plasma SP and CGRP were detected by radioimmuno﹣assay before and after the treatment, while the visual analogue scales ( VAS) were measured. Results:The clinical efficiency of PGB was 89. 1%, that of CBZ was 72. 1%, and there was a significant difference between the two groups (P<0. 05). The treatments re﹣duced plasma SP and CGRP levels in both groups, and the change of PGB group was more obvious than that of CBZ group (P<0. 05). The incidence rate of adverse effect by PGB (31. 3%) was less than that by CBZ (59. 1%) (P<0. 05). Conclusions: The efficacy and safety of PGB for the patients with PTN are superior to those of CBZ.